Unn Ljøstad and Åse Mygland Jone Furlund Owe and Nils ... - ACNR

than just a gap between seizures
Life with epilepsy can be much more
It’s hard to live life to the full if part of you is always expecting
the next seizure. NEW VIMPAT ® is an anti-epileptic drug with an
innovative mode of action. 1,2 In clinical trials, VIMPAT ®
has
shown improved seizure control when added to first and second
generation AEDs. 3 Prescribe VIMPAT ® when you want your patients
to look forward with the confi dence of additional seizure control. 1,3
Confidence of additional seizure control
relevant interaction with ethinylestradiol and levonorgestrel. No effect
on pharmacokinetics of digoxin. Pregnancy and Lactation: Should not
be used during pregnancy. For precautionary measures, breast
feeding should be discontinued during treatment with lacosamide.
Driving etc.: Patients are advised not to drive a car or operate other
potentially hazardous machinery until they are familiar with the effects
of VIMPAT on their ability to perform such activities. Adverse Effects:
Very common (≥10%): Dizziness, headache, diplopia, nausea.
Common (between 1%-10%): Depression, balance disorder, abnormal
coordination, memory impairment, cognitive disorder, somnolence,
tremor, nystagmus, blurred vision, vertigo, vomiting, constipation,
flatulence, pruritus, gait disturbance, asthenia, fatigue, fall, skin
laceration. Adverse reactions associated with PR prolongation may
occur. Consult SPC in relation to other side effects. Pharmaceutical
Precautions: Tablets: None. Syrup: Do not store above 30°C. Use
within 4 weeks of first opening. Solution for infusion: Do not store
above 25°C. Use immediately. Legal Category: POM. Product Licence
Numbers: 50 mg x 14 tabs: EU/1/08/470/001; 100 mg x 14 tabs:
EU/1/08/470/004; 100 mg x 56 tabs: EU/1/08/470/005; 150
mg x 14 tabs: EU/1/08/470/007; 150 mg x 56 tabs:
EU/1/08/470/008; 200 mg x 56 tabs: EU/1/08/470/011; Syrup
(15 mg/ml) x 200 ml: EU/1/08/470/014; Solution for Infusion (10
mg/ml) x 20 ml: EU/1/08/470/016. NHS Cost: 50 mg x 14 tabs:
£9.01; 100 mg x 14 tabs: £18.02; 100 mg x 56 tabs: £72.08; 150
mg x 14 tabs: £27.03; 150 mg x 56 tabs: £108.12; 200 mg x 56
tabs: £144.16; Syrup (15 mg/ml) x 200 ml: £38.61; Solution for
Infusion (10 mg/ml) x 20 ml: £29.70. Name and Address of PL
Holder: UCB Pharma S.A., Allee de la Recherche 60, B-1070
Bruxelles, Belgium. Further information is available from: UCB
Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE. Tel:
01753 534655. Fax: 01753 536632. Email: medicalinformation@
ucb-group.com. Date of Revision: September 2008. VIMPAT is a
registered trade name. References: 1. VIMPAT ®
Summary of Product Characteristics, September
2008. 2. Beyreuther BK et al. CNS Drug Rev 2007;
13(1): 21–42. 3. UCB Data on file. Date of
preparation: September 2008. 08VPE0188
Adverse events should be reported. Reporting forms and
information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to UCB Pharma Ltd.